Beaumont seeks volunteers for study
Beaumont Hospital in Royal Oak seeks volunteers for a national study to test the safety and effectiveness of an investigational COVID-19 vaccine known as AZD1222.
“Because there is currently no FDA- approved vaccine to prevent COVID-19, we’re eager to have Beaumont participate as one of the trial sites. Beaumont Health cared for the most COVID-19 patients in Michigan during the surge in March and April,” said Christopher Carpenter, M.D., principal investigator for the study site and chair of the Department of Medicine, Beaumont, Royal Oak. “We’re hopeful the study will attract a diverse group of participants.”
Researchers are seeking:
• People 18 years of age or older, in good or stable health. They may have an underlying medical condition and still take part, if their disease is stable.
• Individuals with an increased risk of getting COVID-19 or those at greater risk of developing complications from COVID-19.
• Those who do not have a previously confirmed diagnosis of COVID-19.
The Phase 3 research, known as the AZD1222 COVID-19 Vaccine Study seeks about 40,000 participants nationwide.
Two-thirds of the study volunteers will receive the investigational vaccine, and the other onethird will receive a placebo. Participants will be followed for approximately two years.
The Phase 3 trial is part of Operation Warp Speed, a collaboration led by the U.S. Department of Health and Human Services
“This large- scale study definitely has the potential to save lives across our state, the nation and across the globe,” added Matthew Sims, M.D., Ph.D., director of Infectious Diseases Research, Beaumont Health.
All clinic visits will take place at Beaumont Hospital, Royal Oak. Tests will be provided at no cost. Participants will be reimbursed for their time and travel.